Safety and Tolerability of BIII 890 in Patients With Acute Ischemic Stroke

NCT02251197 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

97

Enrollment

INDUSTRY

Sponsor class

Conditions

Stroke

Interventions

DRUG: BIII 890 CL
DRUG: Placebo

Sponsor

Boehringer Ingelheim